261 related articles for article (PubMed ID: 9920366)
21. Effect of postoperative 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer.
Baskin HJ
Thyroid; 1994; 4(3):239-42. PubMed ID: 7833657
[TBL] [Abstract][Full Text] [Related]
22. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
23. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
[TBL] [Abstract][Full Text] [Related]
24. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
26. Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy.
Takeshita Y; Takamura T; Minato H; Misu H; Ando H; Yamashita T; Ikeda H; Nakanuma Y; Kaneko S
Intern Med; 2008; 47(19):1709-12. PubMed ID: 18827421
[TBL] [Abstract][Full Text] [Related]
27. [Limited radical approach in differentiated thyroid gland cancers. A prospective study of 107 patients].
Engel U; Kucharski A; Zornig C
Chirurg; 1994 Dec; 65(12):1095-8; discussion 1098-9. PubMed ID: 7851141
[TBL] [Abstract][Full Text] [Related]
28. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
30. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Terris DJ
Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
[No Abstract] [Full Text] [Related]
31. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy.
Sera N; Ashizawa K; Ando T; Ide A; Abe Y; Usa T; Tominaga T; Ejima E; Hayashi T; Shimokawa I; Eguchi K
Thyroid; 2000 Nov; 10(11):975-9. PubMed ID: 11128725
[TBL] [Abstract][Full Text] [Related]
32. Familial syndromic papillary thyroid carcinoma report of two cases.
Mogoş V; Mogoş S; Sfarti C; Băcăuanu R; Huţanu O; Cotea E; Ciobanu D; Tudorache C; Târcoveanu E
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1048-54. PubMed ID: 23700887
[TBL] [Abstract][Full Text] [Related]
33. The indications for ablating normal thyroid tissue with 131I in differentiated thyroid cancer.
Goolden AW
Clin Endocrinol (Oxf); 1985 Jul; 23(1):81-6. PubMed ID: 3896581
[No Abstract] [Full Text] [Related]
34. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
35. Adrenal metastasis secondary to papillary thyroid carcinoma.
Koutkia P; Safer JD
Thyroid; 2001 Nov; 11(11):1077-9. PubMed ID: 11762719
[TBL] [Abstract][Full Text] [Related]
36. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
37. The role of external beam radiotherapy in the treatment of papillary thyroid cancer.
Lee N; Tuttle M
Endocr Relat Cancer; 2006 Dec; 13(4):971-7. PubMed ID: 17158749
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.
Lin JD; Chao TC; Hsueh C
Clin Endocrinol (Oxf); 2007 Feb; 66(2):224-8. PubMed ID: 17223992
[TBL] [Abstract][Full Text] [Related]
39. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
40. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
